Trabectedin Patent Expiration

Trabectedin was first introduced by Janssen Products Lp in its drug Yondelis on Oct 23, 2015.


Trabectedin Patents

Given below is the list of patents protecting Trabectedin, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Yondelis US8895557 Pharmaceutical formulations of ecteinascidin compounds Jan 07, 2028 Janssen Prods
Yondelis US8895557

(Pediatric)

Pharmaceutical formulations of ecteinascidin compounds Jul 07, 2028 Janssen Prods


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Trabectedin's patents.

Given below is the list recent legal activities going on the following patents of Trabectedin.

Event Date Patent/Publication
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 25 May, 2022 US8895557
Change in Power of Attorney (May Include Associate POA) 01 Jul, 2020 US8895557
Email Notification 01 Jul, 2020 US8895557
Correspondence Address Change 29 Jun, 2020 US8895557
Email Notification 18 Jun, 2020 US8895557
Change in Power of Attorney (May Include Associate POA) 18 Jun, 2020 US8895557
Payment of Maintenance Fee, 4th Year, Large Entity 25 May, 2018 US8895557
Patent Issue Date Used in PTA Calculation 25 Nov, 2014 US8895557
Recordation of Patent Grant Mailed 25 Nov, 2014 US8895557
Email Notification 06 Nov, 2014 US8895557



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳